The cell line with two rounds of lentiviral transduction (higher expression of FBP1, Supplementary Figure S1) demonstrated a significantly higher percentage (CD14+: 27.05%) of viable CD14+ blasts (a biomarker of monocytic differentiation [17]) when compared to both the naïve control (CD14+: 1.287%) and the cell line (CD14+: 5.14%) with only one round of FBP1 lentiviral transduction, indicating that increased FBP1 overexpression could lead to enhanced differentiation of leukemia cells (Figure 2B). The gene discussed is FBP1; the disease is leukemia.